Abstract 3821
Background
Mature oocyte vitrification and storage is currently used to help patients preserving their ability to have offspring either for fertility preservation (FP) before gonadotoxic treatment such as chemotherapy or for elective purposes. Our meta-analysis investigated whether letrozole co-administration during controlled ovarian stimulation (COS) for FP is effective and safe.
Methods
A literature search using PubMed was conducted up to March 8th, 2019 to retrieve information from studies that compared the performance of COS with or without letrozole co-administration for FP. Mean or median values and 95% confidence intervals (CIs) or standard deviations (SDs) were collected for efficacy (number of collected oocytes, number of mature oocytes, maturation rate) and safety (peak estradiol levels [E2], total gonadotropin dose, number of stimulation days) endpoints. Statistical analysis was conducted with random-effects model.
Results
A total of 10 articles were eligible including 1930 patients undergoing COS with or without letrozole. Studies compared COS with and without letrozole in cancer or infertile cohorts (N = 9) and infertile cohort only (N = 1). The total number of oocytes and mature oocytes collected were similar between letrozole and no letrozole groups while the peak estradiol was significantly higher in the standard COS without letrozole (Table).Table:
1829P
MR (letrozole vs no letrozole) | 95% CI | P-value | |
---|---|---|---|
Collected oocytes | 1.02 | 0.90-1.16 | 0.748 |
Mature oocytes | 0.98 | 0.83-1.16 | 0.830 |
Maturation rate | 0.94 | 0.86-1.03 | 0.181 |
Peak E2 | 0.27 | 0.22-0.32 | <0.001 |
Total gonadotropin | 0.97 | 0.86-1.10 | 0.676 |
Length of stimulation | 1.00 | 0.95-1.04 | 0.849 |
Conclusions
Letrozole co-administration during COS resulted to be as effective as standard COS but with significantly decreased peak estradiol levels, suggesting its increased safety especially for hormone-sensitive cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3620 - Safety, efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours
Presenter: Wolfgang Wick
Session: Poster Display session 1
Resources:
Abstract
5465 - Proof of concept clinical study by US-guided intratumor injection of VCN-01, an oncolytic adenovirus expressing hyaluronidase in patients with pancreatic cancer
Presenter: Manuel Hidalgo
Session: Poster Display session 1
Resources:
Abstract
2555 - A Phase 1a/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumors
Presenter: John Sarantopoulos
Session: Poster Display session 1
Resources:
Abstract
3533 - First in human phase 1/2a study of PEN-866, a Heat Shock Protein 90 (HSP90) ligand – SN38 conjugate for patients with advanced solid tumors: Phase 1 results
Presenter: Johanna Bendell
Session: Poster Display session 1
Resources:
Abstract
4114 - A Phase I Open-Label, Non-Randomized Study of Recombinant Super-Compound Interferon (rSIFN-co) In Patients with Advanced Solid Tumors
Presenter: Amanda Seet
Session: Poster Display session 1
Resources:
Abstract
2537 - Evaluation of Pharmacodynamic (PD) Biomarkers in Advanced Cancer Patients Treated with Oxidative Phosphorylation (OXPHOS) Inhibitor, OPC-317 (OPC)
Presenter: Jie Qing Eu
Session: Poster Display session 1
Resources:
Abstract
5764 - Pharmacokinetic (PK) assessment of BT1718: A phase 1/2a study of BT1718, a first in class Bicycle Toxin Conjugate (BTC), in patients (pts) with advanced solid tumours
Presenter: Natalie Cook
Session: Poster Display session 1
Resources:
Abstract
2683 - A phase I open label dose escalation trial evaluating VT1021 in patients with advanced solid tumors.
Presenter: Wael Harb
Session: Poster Display session 1
Resources:
Abstract
3609 - Interim Results from Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors
Presenter: Judy Wang
Session: Poster Display session 1
Resources:
Abstract
3485 - Phase 1 Trial of Fruquintinib in Patients with Advanced Solid Tumors: Results of the Dose Escalation Phase
Presenter: Andrea Wang-Gillam
Session: Poster Display session 1
Resources:
Abstract